

31 March 2017

- | | |
|---|---|
| <p>(1) BSE Ltd
Listing Department
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai - 400 001</p> | <p>(2) National Stock Exchange of India Ltd
Listing Department
Exchange Plaza, 5th floor,
Plot no. C/1, G Block,
Bandra Kurla Complex,
Bandra (East), Mumbai - 400 051</p> |
|---|---|

Scrip Code: 500087

Scrip Code: CIPLA EQ

- (3) SOCIETE DE LA BOURSE DE LUXEMBOURG
Societe Anonyme
35A Boulevard Joseph II,
L-1840 Luxembourg

Dear Sirs,

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform that the Company's wholly owned subsidiary Cipla Medpro South Africa (Pty) Limited has signed an agreement on SA Time, 30 March 2017 (i.e. IST, 31 March 2017) to acquire 100% stake in Anmaraté (Pty) Limited, South Africa.

The details as required under the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 are enclosed as Annexure – I.

Thank you,

For Cipla Limited




Rajendra Chopra
Company Secretary

Encls:

1. Details as per the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Annexure - I

Sr. No.	Particulars	Details
a)	Name of the target entity, details in brief such as size, turnover etc.;	Anmaraté (Pty) Limited ("Anmaraté") It has revenue of ZAR 2.5 million for financial year ending on 29 Feb 2016.
b)	Whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at "arms length";	Acquisition doesn't fall within the purview of related party transaction.
c)	Industry to which the entity being acquired belongs;	Pharmaceutical business
d)	Objects and effects of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity);	Acquisition of the business of Anmaraté to strengthen market position etc.
e)	Brief details of any governmental or regulatory approvals required for the acquisition;	Requisite statutory and regulatory approval
f)	Indicative time period for completion of the acquisition	The transaction expected to be completed before 14 April 2017
g)	Nature of consideration - whether cash consideration or share swap and details of the same;	Cash consideration



h)	Cost of acquisition or the price at which the shares are acquired	ZAR 26,253,659 (subject to post-closing adjustment of net working capital, not exceeding ZAR 30 million)
i)	Percentage of shareholding / control acquired and / or number of shares acquired;	4000 ordinary shares of ZAR 1 each representing 100% of the Anmarate's share capital.
j)	Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief)	Anmarate was incorporated on 29 th August 1996 in South Africa and is engaged in manufacturing and distribution of pharmaceutical products. The turnover of the Anmarate for the financial year 2013-14, 2014-15 and 2015-16 were ZAR 3.2 million, ZAR 2.8 million and ZAR 2.5 million respectively.

